A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

a.sfakia shared this article with you from Inoreader A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma Via Cancer British Journal of Cancer, Published online: 14 December 2020; doi:10.1038/s41416-020-01180-1 A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.